MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
Active, not recruiting · NCT02285816 · Registry updated 2026-03-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours | Advanced/Metastatic Solid Tumours | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-09 | NCT02285816 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Cancer Trials Group | 73 |
| Ottawa Hospital Research Institute | 121 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BCCA - Vancouver Cancer Centre | Vancouver | Canada | 11 |
| Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Canada | 60 |
| Ottawa Hospital Research Institute | Ottawa | Canada | 46 |
| University Health Network | Toronto | Canada | 52 |